Hypera S.A. Hypera S.A.

Hypera S.A.

HYPE3

Rang in aandelen #4245
Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical... Based in São Paulo, Brazil, Hypera S.A. is a prominent pharmaceutical enterprise. The company's comprehensive product line encompasses a wide array of prescription medications, featuring established brands such as Adacne, Celestamine, Cizax, Diprosone, and Emprol XR, among many others. Beyond prescription drugs, Hypera offers specialized dermo-cosmetics through its Mantecorp Skincare brand. Its consumer health division markets popular remedies like Apracur, Benegrip, Engov, and Estomazil. Additionally, Hypera provides nutritional and vitamin supplements, including well-known names such as Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal. The company also maintains a significant presence in the generic and similar medicines market, offering products under the Neo Química brand and common formulations like Ibuprofen, Paracetamol, and Omeprazole. The organization officially became Hypera S.A. in February 2018, having previously operated as Hypermarcas S.A.
Aandeelprijs
$5.33
Marktkapitalisatie
$3.75B
Verandering (1 dag)
2.16%
Verandering (1 jaar)
25.26%
Land
BR
Handel Hypera S.A. (HYPE3)

Categorie

Healthcare
Winst voor Hypera S.A. (HYPE3)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Hypera S.A. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Hypera S.A. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten